Tebao Biotech announced that the company issued 1,533 billion yuan of convertible corporate bonds to unspecified targets for a period of 6 years. After deducting the issuance fee, the actual net capital raised was 1,518 billion yuan, which was paid on August 3, 2026. The company has opened special accounts to raise capital, which are 671 million yuan for new drug research and development projects, 450 million yuan for biotechnology innovation integration center construction projects, and 401 million yuan for Tebao Biotech Innovative Drug Production and Expansion Project - Production Line Construction. The company, Guojin Securities and various supervising banks signed the “Tripartite Supervision Agreement for Special Account Storage of Raised Funds”.

Tebao Biotech announced that the company issued 1,533 billion yuan of convertible corporate bonds to unspecified targets for a period of 6 years. After deducting the issuance fee, the actual net capital raised was 1,518 billion yuan, which was paid on August 3, 2026. The company has opened special accounts to raise capital, which are 671 million yuan for new drug research and development projects, 450 million yuan for biotechnology innovation integration center construction projects, and 401 million yuan for Tebao Biotech Innovative Drug Production and Expansion Project - Production Line Construction. The company, Guojin Securities and various supervising banks signed the “Tripartite Supervision Agreement for Special Account Storage of Raised Funds”.